AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.
Bayer said meeting its 2018 forecasts for consumer health and animal health segments now seems increasingly ambitious.
Critics have blasted AstraZeneca’s rummage-sale strategy as unsustainable, but CEO Pascal Soriot says it's vital for bottom-line growth.
Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.
Tecentriq is on its way to becoming the first immuno-oncology drug with an approval in triple negative breast cancer, and that path just got shorter.
When does CMI/Compas exec Paul Kallukaran think pharma should start working machine learning in their marketing strategies? "Yesterday."
Some critics said the abnormal trends in key CV biomarkers in the placebo arm has compromised the otherwise exciting data.
Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.
Vertex has been at a standstill with U.K. authorities over Orkambi, and now MPs are adding to the pressure for the sides to make a deal.
Months after world regulators first discovered impurities in the ingredient of a Chinese ingredient maker, tainted drugs continue to show up in the U.S. supply.